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Abstract
With increased use of medical imaging, the incidental detection of benign solid liver tumors has become more frequent. 
Facing with benign disease, the indications for surgery are still object of discussion in light of the stable natural course of 
most lesions and obvious drawbacks of any surgical intervention; therefore, in most situations, a conservative approach is 
recommended, and surgery is mainly reserved for those cases with persistent or worsening symptoms, or who are at risk for 
complications as malignant transformation. The advent of ablative techniques has widened the range of treatment options 
available to these patients, presenting as a valid alternative to resection in terms of safety and efficacy in selected cases, 
particularly in patients who are considered poor surgical candidates and with smaller lesions. This review outlines the role of 
percutaneous ablative methods for benign solid liver tumors that are encountered in adults, providing a per histology analysis 
of the existing evidence. The up-to-date strategies for management of the most common benign solid tumors are recapitulated.
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Introduction
Over the past decades, the dramatic rise in abdominal imag-
ing has led to a steady increase in the incidental detection of 
asymptomatic lesions, including benign liver tumors (BLT). 
BLT are a diverse group of lesions with different cellular 
origins, in which clonal analysis has shown a spectrum of 
regenerative and neoplastic features [1]. They are relatively 
frequent, since autopsy series have reported incidences 
up to 50% [2]. BLT are generally classified into solid and 
cystic based on imaging characteristics; among them, cystic 
tumors probably occur more frequently than solid ones [3]. 
Hemangiomas (HH), focal nodular hyperplasia (FNH) and 
hepatocellular adenoma (HCA) are the most common solid 
BLT [4].
With the increasing detection of BLT during cross-sec-
tional imaging obtained for other reasons, it is quite clear 
that clinicians are more frequently faced with the dilemma 
regarding the management of these findings. The trend 
toward a conservative approach for accidentally discovered 
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liver lesions entails an accurate diagnosis to reassure both 
the patient and the clinician regarding the specific type of 
lesion and, consequently, its natural history. Thanks to the 
constant improvement of imaging modalities and better 
understanding of complications related to different histolo-
gies, most BLT can be managed safely with observation 
alone [4]. Therefore, radiological data are crucial for restrict-
ing the number of percutaneous biopsies and the resections 
performed for final diagnosis [5].
Some of these lesions, however, are of greater clinical rel-
evance than others, because of risks of complications includ-
ing significant clinical symptoms and potential malignant 
change [2, 4, 6].
Facing with benign disease, the indications for surgery 
may be variable and somewhat subjective, mainly reserved 
for those cases with persistent or worsening symptoms and 
suspicion of malignant transformation [2, 3], in light of the 
obvious drawbacks of almost any surgical intervention.
In the last decades, percutaneous minimally invasive pro-
cedures have advanced considerably, and this widespread 
use represents the result of a varied combination of factors 
including the reduction of peri-operative complications and 
postoperative recovery time, the development and refinement 
of new technologies, and patient awareness of emerging 
therapeutic approaches [7]. These therapies have therefore 
gained great attention and widespread clinical acceptance as 
valuable methods for treating focal malignancies in a diverse 
spectrum of tumor types and tissues.
Even in the setting of BLT, percutaneous ablative proce-
dures may represent a possible alternative.
This review describes the existing evidence about the 
use of percutaneous ablative procedures for the treatment 
of solid benign liver lesions.
Materials and methods
In this study, we adhered to the standard guidelines of Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [8].
An extended systematic search in Medline database (via 
PubMed) including articles related to human medicine was 
performed by two independent physicians (FP and ACo) 
with experience in literature search strategies and data 
extraction.
On the basis of the PICO methodology, articles were 
selected according a priori inclusion criteria: (a) population 
was identified as subjects aged > 18 years with an established 
BLT diagnosis; (b) intervention as percutaneous ablation 
through different techniques; (c) outcome as feasibility, 
safety, clinical outcomes or prognosis for this kind of inter-
vention; (d) type of study as controlled or comparative, rand-
omized or nonrandomized experimental studies, prospective 
or retrospective observational studies, including also case 
series (> 3 patients); (e) works written in English.
The search strategy was elaborated to include the greatest 
number of references dealing with the populations and the 
interventions object of the study by using the following key-
words in combination with the Boolean operators AND and 
OR: “ablation”, “hemangioma”, “hepatic adenomas”, “liver 
neoplasms”; studies regarding the treatment of hepatocel-
lular carcinoma or liver metastases were excluded by using 
the keywords “hepatocellular carcinoma”, “metastasis” with 
the Boolean operators NOT.
The literature search was not restricted to any publica-
tion date.
At first, the reviewers checked the results at both the title 
and abstract level. Then, the full texts of the selected stud-
ies were retrieved and reference lists were manually cross-
checked to find any relevant study that was missed with our 
search strategy but met the prespecified PICOS criteria. In 
case of disagreement between the two reviewers, a further 
author (ACa) was consulted to achieve a consensus.
Data from the selected studies were collected into a stand-
ardized form.
Results
The search strategy provided 2096 potentially relevant 
citations. After removal of case reports, case series (≤ 3 
patients), reviews, guidelines, and original articles not in 
the field of interest, and after accurate check of reference 
lists of the full-text articles retrieved, there were finally 22 
studies which fulfilled the inclusion and exclusion criteria 
(Fig. 1). The characteristics of the original articles included 
are summarized in Table 1.
We provide below a per histology analysis of the results.
Adenoma
Seven retrospective studies dealing with percutaneous abla-
tion of BLTs including HCAs were selected in the present 
work.
Patient characteristics
Rhim et al. [9] treated eight asymptomatic patients and two 
patients with recurrent tumor after surgical resection who 
refused to undergo any further surgical procedure or con-
servative management by imaging follow-up. Two patients 
presented with liver cirrhosis related to virus B infection or 
alcoholic abuse, while no patient had predisposing factors 
for HCA, such as history of oral contraceptives or steroid 
therapy. No signs of cirrhosis were reported in other studies 
[10–13]. The patients treated in the other series were mostly 
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asymptomatic except for a declared history of HCA-related 
hemorrhage present only in 11% and 22% of cases [10, 12]. 
The use of oral contraceptives was the main predisposing 
factor [10–12].
The decision to pursue percutaneous ablation therapy was 
based on a multidisciplinary discussion [12, 13], or estab-
lished considering multiple factors. Ablation was performed 
in patients not amenable to surgery in view of comorbidi-
ties, location or number of the lesions, or in cases other-
wise requiring large liver resections [10, 13], owing to an 
expected lower rate of procedural complications compared 
with surgery [13]. Van Vledder et al. treated 18 women with 
HCAs and, in this population, the desire to become pregnant 
was a relevant motivation to consider the intervention [10].
General contraindications were: severe blood coagulation 
dysfunction, active inflammatory or infectious process, acute 
or severe renal insufficiency, pulmonary or cardiac dysfunc-
tion [14]. If the lesion was uncertain for malignancy based 
on radiologic examination alone, surgery was considered the 
treatment of choice [10].
In most patients the diagnosis was confirmed by biopsy 
after imaging evaluation and prior to ablation, except for 
one patient [13] in which clinical and imaging findings were 
highly suggestive for HCA and biopsy was not obtained, and 
a series [10] in which the diagnosis was based on radiology 
data alone, including contrast-enhanced magnetic resonance 
(MR) and multiphasic computed tomography (CT) imaging.
Ablation procedures
Percutaneous radiofrequency (RF) or microwave (MW) abla-
tion were used for all patients under US, CT, or combined 
guidance. RF or MW ablation (RFA, MWA) time varies 
among the series, with total procedure times ranging from 
averages of 3 to 22 min depending on the different series and 
techniques employed [9–12]. Van Veddler et al. compared 
the use of a CT-guided percutaneous approach to an open 
approach in which US-guided RF ablation was combined 
with resection, strategy applied also in some patients with 
liver adenomatosis (i.e., ≥ 10 nodules) [10].
Procedural and clinical outcomes
Rhim et al. reported 100% primary efficacy rate with com-
plete ablation without any residual viable tumor at post-
procedural imaging [9]. Comparing percutaneous to open 
ablation, Van Vledder and colleagues found a significant 
difference in primary efficacy, with a higher percentage in 
the open ablation group than in the percutaneous ablation 
group (79% and 31%, respectively; p = 0.013). The rate of 
local technical failures reported in this study is relatively 
high, with 50% of patients requiring more than one RF abla-
tion sessions to obtain a satisfactory treatment of all HCAs 
[10]. According to the data reported by Costa et al., only one 
out of 26 (4%) ablated HCAs showed evidence of residual 
disease at the first follow-up imaging with nodular or irregu-
lar enhancement, subsequently treated to complete ablation 
after a repeated session [11]. Moreover, they showed that fat 
tissue found in the ablation zone did not seem to be related to 
the residual tumor but was associated with significant stea-
tosis and/or intratumoral fat [11]. Mironov et al. described 
complete ablation after the first treatment session in 88% 
of cases with total response with further ablative sessions 
[12]. Smolock et al. successfully treated 12 HCAs of which 
only one lesion of 8.3 cm diameter underwent two planned 
ablation sessions, therefore with a primary efficacy of 100% 
[13]. No local tumor progression, malignant transformation, 
hemorrhage or death were reported in these studies during 
follow-up periods [9, 12, 13].
Complications
The complication rate for the procedures reported among the 
selected studies is low. Two immediate post-procedural hem-
orrhages (4.5% per procedure) were described [12]: in one 
patient treated with MWA and in a patient who underwent 
Fig. 1  Flow chart shows sum-
mary of the literature review 
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overlapped ablation and subsequent arterial embolization 
with absorbable gelatin sponge. Van Vledder et al. described 
two main complications related to the procedure (class D as 
defined by the Society of Interventional Radiology (SIR) 
classification system): in a patient who underwent an open 
RFA with persistent oval foramen and consequent cerebral 
ischemia, and in another patient who developed an hepatic 
abscess in the site of ethanol injection performed after per-
cutaneous RFA for two HCAs [10].
Hemangioma
Patient characteristics
In all the 17 studies, reviewed diagnosis of HH was con-
firmed by imaging based on the typical enhancement pat-
tern on contrast-enhanced CT, MR or contrast-enhanced 
ultrasound (CEUS). In one study by Wang et al., prepro-
cedural blood tests were performed to exclude malignant 
neoplasm (AFP, CEA and CA19-9) [15]. Indication to resort 
to ablative percutaneous strategies were mostly homogene-
ous among the considered studies, including the presence of 
“large/giant” HH associated to persistent-related symptoms 
in patients refusing open or laparoscopic surgical resection. 
Only discrepancy, though minor, was found in the defini-
tion for “large” HHs. Specifically, both Liu and Ziemle-
wick considered for treatment lesions greater than 4 cm, 
while all other studies referred to a cut-off of 5 cm [16, 17]. 
Reported symptoms included abdominal pain or distension, 
anemia, portal hypertension, obstructive jaundice, coagu-
lopathy (Kasabach–Merritt syndrome) or serious psycho-
logical effects consequent to the diagnosis. Also, most of 
the authors considered the tendency to enlarge of an imag-
ing proved HH as an inclusion criterion (more than 0.5 cm 
within one year; more than 1 cm after 2-year follow-up). 
Most common exclusion criteria comprised the presence 
of severe blood coagulation dysfunction, active inflamma-
tion or infection in any organ, acute or severe renal failure 
and cardio-pulmonary insufficiency. A distance lesser than 
0.5 cm between the HH and hollow viscera (especially the 
gastrointestinal tract and gallbladder) and, by extension, 
large subcapsular HHs, were in some of the studies included 
among the reasons for surgery.
Ablation procedures
Percutaneous RFA or MWA were used for all patients under 
US, CT or combined guidance.
Ji and colleagues [18] evaluated the feasibility and effi-
cacy of transarterial embolization (TAE) combined with 
subsequent CT-guided RFA in the treatment of HHs larger 
than 10 cm. The authors found that TAE may facilitate the 
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ablation by reducing the vascular supply and the volume of 
the lesion.
Both Wang and Gao in their series compared CT-guided 
percutaneous RFA to RFA via laparoscopy, with the latter 
author using US as intra-surgical guidance for ablation.
Tang and colleagues compared different surgical tech-
niques, both laparotomic and laparoscopic, with percutane-
ous MWA [19–22].
A 3D visualization operative planning system revealed 
to be a valuable tool in providing detailed anatomical data 
and, therefore, individualized therapy for HHs by US-guided 
MWA [23].
In 4 out of 17 studies, authors performed preprocedural 
peritoneal saline infusion (hydrodissection) to provide a 
satisfactory sonographic window and to protect nontarget 
structures (diaphragm, abdominal wall, colon, gallbladder) 
while ablating lesions abutting the Glisson capsule or the 
diaphragm [15, 17, 23–25].
Procedural time varies among the series and in accord-
ance to the specific percutaneous ablation techniques pro-
posed, ranging from 11,6 to 117 min. Significant shorter 
procedural time was observed for percutaneous MWA 
(22,40 ± 8,45 min) compared to percutaneous RFA tech-
niques (74,64 ± 29,87 min). However, ablation time varied 
conspicuously within each series depending on the size of 
the treated lesion.
Procedural and clinical outcomes
While no technical failure was reported among the stud-
ies evaluated, procedure effectiveness rate varied with the 
specific ablation technique considered. Li and Wang, which 
used MW energy under US guidance, reported a rate of com-
plete tumoral ablation of 95.9% and 84.6%, respectively [19, 
23]. In the study by Liu F and colleagues the mean tumoral 
volume shrinkage rate was 59.67% within three days after 
US-guided MW ablation [16]. A complete ablation rate of 
93.3% after combined application of percutaneous RF and 
TAE was reported by Ji et al. in their retrospective series 
[18]. In the comparison of percutaneous MWA and surgical 
resection described by Tang and colleagues no statistically 
significant difference in effectiveness was noted between the 
two groups (p 0.58), with the latter entailing higher hospi-
talization length and overall worse patient performance [26]. 
Despite the differences in the follow-up times and protocols, 
the majority of the studies reported an overall clinical effec-
tiveness of the procedures, with pain relief or improvement 
of symptoms. In the 2014 study by Ziemlewicz et al., pain 
score evaluated on the visual analogue scale at 1- to 6-month 
follow-up decreased from an average of 4.6–0.9 (p 0.05), 
with patients able to return to their pre-procedure level of 
activity within a week after percutaneous MWA [17].
Complications
Wang and Cheng described the development of post-ablation 
systemic inflammatory response (SIR) in 50% and 75.7% 
of patients, respectively, within two days after intervention 
[14, 19]. Wang and colleagues reported low fever, consti-
pation, slight wound pain, stomach discomfort and other 
MWA minor postoperative reactions in 11 out of 12 treated 
patients [15]. Transient and rapidly resolving liver dysfunc-
tion, manifesting as elevation of serum alanine transaminase 
and aspartate transaminase (> 80 U/L) and jaundice do to 
indirect hyperbilirubinemia over 3 mg/dl were described in 
three studies [18, 23, 25]. Acute kidney insufficiency (AKI) 
was an infrequent complication among the studies consid-
ered. Notably, Li et al. [24] investigated the risks factors 
for hemoglobinuria following liver ablation, including both 
malignant (primary or metastatic) and benign tumors; they 
showed that 17 out of 57 patients (29.8%) diagnosed with 
HHs and treated via MWA developed haemoglobinuria, 
which was higher than the incidence in primary liver cancer 
(5.4%) and in metastatic disease cases (3.3%). Moreover, 
the only patient who progressed to acute renal failure was 
diagnosed with HH.
Minor chest and abdominal complications, such as tran-
sient pleural effusion and ascites, were not uncommon 
among the selected articles.
Gao and colleagues described two cases of post-ablative 
diaphragmatic rupture (grade III of Clavien–Dindo classifi-
cation), while Tang and colleagues reported the development 
of diaphragmatic hernia in one patient [22, 26].
Apparently no permanent sequelae or other severe com-
plications, including abscesses, major bile duct injury, gas-
trointestinal tract perforation and hemorrhage requiring sur-
gery or embolization, did occur in the periprocedural and 
follow-up periods.
Other histologies
A few studies [14, 24, 27] dealt with the percutaneous abla-
tion of BLTs different from HHs and HCAs. These series 
were mostly heterogeneous in terms of tumor histology and 
treatment strategy.
Yang and colleagues [27] treated 92 hepatic angiomyoli-
pomas; 22 lesions were approached using US-guided RFA 
after biopsy in case of tumor size less than 5 cm and lesions 
highly suspected for angiomyolipomas after imaging evalu-
ation. No major complications were reported.
MWA under US guidance was employed by Cheng el 
al. [14] to treat diverse BLT subtypes, including 5 FNHs, 6 
inflammatory pseudotumors, 5 solitary necrotic nodules, 3 
angiomyolipomas, and 1 epithelioid hemangioendothelioma. 
The patients selected to undergo ablation had an indetermi-
nate diagnosis on the basis of imaging features, an enlarging 
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benign nodule (greater than 1 cm within one year); were at 
risk of malignant evolution; had symptoms supposed to be 
associated with the BFL presence; or heavy psychological 
pressure for the detection of an hepatic neoplasm, despite a 
definite diagnosis of a benign condition. Biopsy was rou-
tinely performed prior to ablation, and, in case of nodules 
that were indeterminate for malignancy, the ablation volume 
included 5–10 mm of normal liver tissue surrounding the 
target lesion. Residual disease was found in one FNH, com-
pletely re-treated with a second ablative session for rapid 
tumor growth. No major complications were registered.
In their aforementioned work, Li et al. [24] investigated 
the risks factors for hemoglobinuria following liver abla-
tion, including both malignant and benign tumors, the latter 
including FNH cases.
Discussion
Adenoma
HCA is a rare solid BLT with a prevalence reported between 
0.001 and 0.004%, being more commonly encountered in 
females of childbearing age [2]. Use of oral contraceptives, 
anabolic steroids and glycogen storage disease are known 
factors associated with the onset of this subtype of BLT. The 
risk of hemorrhage, rupture and malignant transformation 
into hepatocellular carcinoma, particularly in the β-catenin-
mutated subtype, makes recognition and management cru-
cial [28]. A systematic review has reported an overall risk 
of rupture and subsequent hemorrhage of 27.2% among 
patients, and 15.8% of HCA lesions [29]. Even though the 
risk of malignant change seems rarer (4.2%) [6], this is a 
serious complication which cannot be neglected.
Several approaches are available for the management of 
HCAs. A conservative strategy using imaging follow-up is 
preferred for smaller HCAs with a low risk of hemorrhage 
[30]. Albeit surgical resection is considered the standard 
treatment reserved for tumors greater than 5 cm, due to 
concerns about surgical morbidity and prolonged recovery 
time there is interest in treating these benign lesions with 
percutaneous ablation [30]. Several studies have, therefore, 
described the successful application of minimally invasive 
strategies in the treatment of HCAs [9–13].
Beyond the lesion size, other baseline diagnostic imag-
ing features are relevant, as an exophytic protrusion may 
warn against the risk of rupture [2]. Conservative manage-
ment generally consists in imaging follow-up and lifestyle 
change, and is recommended in women with single or mul-
tiple HCA < 5 cm [31]. Surgery instead is required in male 
patients regardless of tumor dimension due to the risk of 
malignant transformation, and is recommended in women 
with nodules with diameter > 5 cm [32]. It should be recalled 
that surgery for HCAs is not devoid of risks: Dokmak et al. 
reported a post-surgical major complications rate of 15%, 
with need for blood transfusions in 13% of patients [32]. No 
cases of death or malignant mutation over a median follow-
up of 70 months were, however, registered [32].
It is now well established that the initial management 
should be as conservative as possible, and aggressive man-
agement should be selectively limited to HCAs at early risk 
of complications [32, 33]. Data collected on the results of 
minimally invasive treatments for HCAs are limited, but the 
current evidence demonstrates a primary efficacy rate rang-
ing from 58 to 100% [9–13]. The local technical failure rate 
seems to be proportional to the increasing lesion size: RFA 
of 45 HCAs with median size of 3.0 cm (range, 0.8–7.3 cm) 
resulted in a relatively low primary efficacy rate of 58% [10]. 
Van Vledder and colleagues have hypothesized that, in addi-
tion to the larger tumor size, the lack of cirrhosis and tumor 
capsule could also contribute to the lower effectiveness of 
RFA [10]. On the contrary, the good results of ablation using 
MWA technology could be justified by the greater volume of 
necrosis produced, by the relative insensitivity to the prop-
erties of the background tissue, and to the greater ability to 
overcome the macro and micro-perfusion conditions [7, 13].
Percutaneous procedures for HCA treatment are generally 
safe, and few complications have been reported. However, 
the limit of such studies is that a comparison with surgi-
cal or conservative techniques could not be made, in terms 
of safety and efficacy, for the lack of a comparison arm. 
Future research on larger cohorts is warranted to explore the 
advantages of minimally invasive techniques compared with 
conservative and surgical approach.
Although further studies are still necessary, we suggest 
that thermal ablation for HCAs should be recommended in 
selected patients, particularly for poor surgical candidates 
and in smaller tumors (< 5 cm), in patients who would 
require otherwise large liver resections, or in which com-
plete surgical removal would not be achievable given the 
multiplicity of HCAs.
Hemangioma
HH is the commonest benign tumor in human liver, with a 
reported incidence rate of 3–20% in the general population 
and of 0.4%–7.3% at autopsy [34, 35]. The pathogenesis 
of HH is poorly understood, possibly reflecting hormonal 
congenital disorders [2]. HHs may have the tendency to 
enlarge over the time, probably due to progressive vas-
cular ectasia rather than true neoplastic proliferation or 
neovascularization [36]. Usually detected incidentally 
during abdominal imaging performed for other indica-
tions, the vast majority of HHs are asymptomatic lesions 
with no need for clinical intervention. HH are frequently 
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small (< 4 cm) and solitary, although “giant” lesions may 
reach 10 cm or more in diameter [2]. “Large” (> 4–5 cm) 
and especially “giant” HH may sometimes be sympto-
matic, with pain and bowel discomfort being the most 
frequently complained symptoms. SIR and coagulopathy 
such as Kasabach–Merritt syndrome (KMS) represent 
rarer manifestations [37]. Although no clear consensus 
has been reached regarding which kind of lesion may be 
susceptible of treatment, therapeutic approach is usually 
proposed for tumors that are significantly growing, causing 
abdominal symptoms or entailing high risk of spontane-
ous or traumatic rupture. A wide spectrum of treatment 
strategies for HHs have been suggested over time. Surgical 
resection and tumor enucleation are used to be the first 
choices for enlarging and symptomatic cases. Although 
surgery can achieve complete removal of the tumor, this 
invasive approach involves relatively long hospitaliza-
tion and periprocedural morbidity and mortality reported 
up to 31.5% and 3%, respectively [38, 39]. Furthermore, 
there is no clear established consensus, either on general 
management or on the most appropriate timing to resort 
to elective surgery, and decision-making is often based 
on the experience of the individual physician and local 
production volume. In recent years, imaging guided mini-
mally invasive approaches have been proposed for the 
treatment of benign liver lesions, including TAE, radia-
tion therapy and different ablation techniques involving 
various types of energy delivery systems. Both RFA and 
MWA have been performed during laparoscopy or percu-
taneously under CT or US guidance. Compared with other 
therapies, percutaneous ablation techniques have been 
increasingly used for the treatment of HHs, having the 
unique advantages of minimal invasiveness, low cost and 
incidence of complications, short hospitalization length 
and increased patient compliance. However, to the best 
of authors’ knowledge, only one consensus attempt was 
made concerning the application of percutaneous ablative 
techniques in the treatment of these lesions, however, lim-
ited to RFA application. TAE and radiation therapy have 
not been considered curative therapies for HHs because 
of their poor results and serious complications, although 
TAE has been considered to manage the KMS, as well as 
medical therapy with corticosteroids or vincristine [37, 
40]. Therefore, ablation therapies are a safe, feasible, and 
effective approach to HHs, even for greater lesions.
Other histologies
FNH is a relatively frequent benign condition of the liver, 
representing the second most common solid BLT with an 
estimated prevalence of 1% [1, 41]. FNH is considered a 
hyperplastic reaction originating from an arterial malfor-
mation, and no instances of malignant transformation have 
been reported in the literature [42]. Most cases are inciden-
tally discovered in asymptomatic subjects; however, albeit 
rarely in patients with large nodules or close to surrounding 
structures abdominal pain or discomfort might be reported.
There is insufficient evidence to support or refute abla-
tion therapies for FNH, given that reassurance regarding the 
stable nature of the lesion and the lack of complications is 
given to patients and constitutes the only suggested manage-
ment strategy in most cases [1, 2]. Moreover, the correlation 
between the presence of FNH and symptoms is poor, and 
treatment is rarely indicated even in symptomatic subjects 
[2], limiting the choice to treat only for exceptional cases 
[14]. At present, there are no published randomized con-
trolled trials comparing the outcomes of TAE or RFA with 
those of either surgery or conservative management.
Hepatic angiomyolipomas are rare mesenchymal neo-
plasms which most commonly arise in the kidney and only 
sporadically develop in the liver parenchyma. They may 
present as solitary mass or as multiple lesions when associ-
ated with tuberous sclerosis and entail a very small malig-
nant potential [1, 27, 42]. Liver biopsy is warranted in most 
patients presenting with lesions suspected for angiomyoli-
pomas, since imaging may be inconclusive due to the rar-
ity of the condition and the frequent resemblance to HCA 
and hepatic carcinoma, especially when the fat component 
is small or unapparent [1, 5]. Conservative management 
is generally recommended for asymptomatic patients who 
agree with follow-up strategy, whereas surgery is reserved 
for larger nodules (greater than 5 cm). RFA may be a valid 
alternative in certain cases, since it has shown to be safe and 
effective in the treatment of smaller lesions; in most of these 
patients with small angiomyolipomas, the drive behind the 
choice of a different approach was psychological pressure 
and consequent strong wish to intervene [27].
Conclusion and outlook
With widespread use of advanced imaging techniques, the 
incidental detection of solid BLTs is constantly increasing, 
thus the physician is more frequently faced with the deci-
sion regarding the management of such conditions. Imaging 
is crucial in the precise definition of histology and natural 
history of the tumor.
The advent of ablative techniques has widened the range 
of treatment options available to these patients, if conserva-
tive approach is not viable and the patient is not eligible for 
surgery. The advantages of ablative procedures compared 
to extirpative surgery include reduced morbidity and faster 
recovery time. Although image-guided percutaneous abla-
tion methods have proved to be safe and effective for treat-
ment of benign liver lesions in selected cases, the current 
evidence is insufficient to make a recommendation, and 
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the decision to pursue ablation rather than surgery requires 
careful consideration: percutaneous ablation may be con-
sidered a valid alternative in patients who are poor surgical 
candidates for comorbidities or multiple lesions, who have 
smaller tumors, BLT-related symptoms or are at risk of com-
plications, or for those who desire to intervene despite the 
reassurance by the physician regarding the benign origin and 
stable natural history of the tumor.
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